Traditional Chinese medicine compounds modulate signaling pathways to improve cardiac-related pathology

被引：0

作者：

Zhang, Luwen ^{[1
,2
]}

Wang, Wei ^{[3
]}

Liu, Xincan ^{[2
]}

Yan, Kuipo ^{[2
]}

Li, Qiang ^{[4
]}

Li, Ming ^{[2
]}

Li, Chunying ^{[1
,2
]}

Li, Yanxin ^{[1
,2
]}

Chen, Lei ^{[2
]}

机构：

[1] Henan Univ Chinese Med, Clin Med Coll 1, Zhengzhou, Henan, Peoples R China

[2] Henan Univ Chinese Med, Affiliated Hosp 1, Heart Ctr, Natl Reg Tradit Chinese Med Cardiovasc Diag & Trea, Zhengzhou, Henan, Peoples R China

[3] Henan Univ Chinese Med, Affiliated Hosp 1, Henan Prov Tradit Chinese Med Epidem Dis Engn Res, Zhengzhou, Henan, Peoples R China

[4] Hena Univ Chinese Med, Affiliated Hosp 1, Henan Key Lab Viral Dis Prevent & Treatment Tradit, Zhengzhou, Henan, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2025年 / 16卷

关键词：

cardiovascular disease; traditional Chinese medicine; nature compounds; signaling pathway; pharmacokinetic; SALVIANOLIC ACID B; ACUTE MYOCARDIAL-INFARCTION; NF-KAPPA-B; ORAL BIOAVAILABILITY; GINSENOSIDE RB1; RATS; PHARMACOKINETICS; PAEONIFLORIN; RESVERATROL; AUTOPHAGY;

D O I：

10.3389/fphar.2025.1499060

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cardiovascular disease poses a significant risk to human health and remains the leading cause of illness and death globally, with its incidence continuing to rise. The intricate pathophysiological mechanisms of CVDs include inflammation, oxidative stress, autophagy, and myocardial fibrosis. In light of these underlying mechanisms, traditional Chinese medicine (TCM) and its constituents have demonstrated distinct advantages in managing CVDs. By exerting synergistic effects across multiple components and targets, traditional Chinese medicine can modulate the inflammatory response, mitigate oxidative stress, regulate excessive autophagy, and enhance myocardial fibrosis repair. This article reviews the latest advancements in understanding how TCM compounds regulate signaling pathways involved in the treatment of CVDs.

引用

页数：20

共 145 条

[71] An update on the regulatory mechanisms of NLRP3 inflammasome activation [J].